Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2025)

Historic Cash from Operations for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$46.5 million.

  • 4D Molecular Therapeutics' Cash from Operations fell 5820.49% to -$46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 6185.3%. This contributed to the annual value of -$134.6 million for FY2024, which is 7757.15% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Cash from Operations stood at -$46.5 million for Q3 2025, which was down 5820.49% from -$43.4 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Cash from Operations ranged from a high of -$1.2 million in Q3 2023 and a low of -$47.8 million during Q1 2025
  • Over the past 5 years, 4D Molecular Therapeutics' median Cash from Operations value was -$23.6 million (recorded in 2022), while the average stood at -$26.5 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Cash from Operations surged by 9442.83% in 2023 and then plummeted by 240990.61% in 2024.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Cash from Operations stood at -$21.8 million in 2021, then dropped by 1.73% to -$22.2 million in 2022, then fell by 10.97% to -$24.6 million in 2023, then tumbled by 86.06% to -$45.9 million in 2024, then decreased by 1.38% to -$46.5 million in 2025.
  • Its Cash from Operations stands at -$46.5 million for Q3 2025, versus -$43.4 million for Q2 2025 and -$47.8 million for Q1 2025.